431 related articles for article (PubMed ID: 36109713)
41. Comparison of SARS-CoV-2 anti-spike receptor binding domain IgG antibody responses after CoronaVac, BNT162b2, ChAdOx1 COVID-19 vaccines, and a single booster dose: a prospective, longitudinal population-based study.
Barin B; Kasap U; Selçuk F; Volkan E; Uluçkan Ö
Lancet Microbe; 2022 Apr; 3(4):e274-e283. PubMed ID: 35165669
[TBL] [Abstract][Full Text] [Related]
42. Safety and immunogenicity of a live-attenuated influenza virus vector-based intranasal SARS-CoV-2 vaccine in adults: randomised, double-blind, placebo-controlled, phase 1 and 2 trials.
Zhu F; Zhuang C; Chu K; Zhang L; Zhao H; Huang S; Su Y; Lin H; Yang C; Jiang H; Zang X; Liu D; Pan H; Hu Y; Liu X; Chen Q; Song Q; Quan J; Huang Z; Zhong G; Chen J; Han J; Sun H; Cui L; Li J; Chen Y; Zhang T; Ye X; Li C; Wu T; Zhang J; Xia NS
Lancet Respir Med; 2022 Aug; 10(8):749-760. PubMed ID: 35644168
[TBL] [Abstract][Full Text] [Related]
43. Clinical Evaluation of the Abbott Alinity SARS-CoV-2 Spike-Specific Quantitative IgG and IgM Assays among Infected, Recovered, and Vaccinated Groups.
Narasimhan M; Mahimainathan L; Araj E; Clark AE; Markantonis J; Green A; Xu J; SoRelle JA; Alexis C; Fankhauser K; Parikh H; Wilkinson K; Reczek A; Kopplin N; Yekkaluri S; Balani J; Thomas A; Singal AG; Sarode R; Muthukumar A
J Clin Microbiol; 2021 Jun; 59(7):e0038821. PubMed ID: 33827901
[TBL] [Abstract][Full Text] [Related]
44. Humoral and cellular immune responses in fully vaccinated individuals with or without SARS-CoV-2 breakthrough infection: Results from the CoV-ADAPT cohort.
Hollstein MM; Dierks S; Schön MP; Bergmann A; Abratis A; Eidizadeh A; Kaltenbach S; Schanz J; Groß U; Leha A; Kröger A; Andag R; Zautner AE; Fischer A; Erpenbeck L; Schnelle M
J Med Virol; 2023 Oct; 95(10):e29122. PubMed ID: 37787583
[TBL] [Abstract][Full Text] [Related]
45. Primary, Recall, and Decay Kinetics of SARS-CoV-2 Vaccine Antibody Responses.
Ibarrondo FJ; Hofmann C; Fulcher JA; Goodman-Meza D; Mu W; Hausner MA; Ali A; Balamurugan A; Taus E; Elliott J; Krogstad P; Tobin NH; Ferbas KG; Kitchen SG; Aldrovandi GM; Rimoin AW; Yang OO
ACS Nano; 2021 Jul; 15(7):11180-11191. PubMed ID: 34159781
[TBL] [Abstract][Full Text] [Related]
46. Mucosal antibody responses following Vaxzevria vaccination.
Selva KJ; Ramanathan P; Haycroft ER; Tan CW; Wang LF; Downie LE; Davis SK; Purcell RA; Kent HE; Juno JA; Wheatley AK; Davenport MP; Kent SJ; Chung AW
Immunol Cell Biol; 2023; 101(10):975-983. PubMed ID: 37670482
[TBL] [Abstract][Full Text] [Related]
47. Characterization of SARS-CoV-2 humoral immune response in a subject with unique sampling: A case report.
Walker MR; Idorn M; Bennett A; Søgaard M; Salanti A; Ditlev SB; Barfod L
Immun Inflamm Dis; 2023 Jun; 11(6):e910. PubMed ID: 37382252
[TBL] [Abstract][Full Text] [Related]
48. Mucosal and Systemic Responses to Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination Determined by Severity of Primary Infection.
Sajadi MM; Myers A; Logue J; Saadat S; Shokatpour N; Quinn J; Newman M; Deming M; Rikhtegaran Tehrani Z; Magder LS; Karimi M; Abbasi A; Shlyak M; Baracco L; Frieman MB; Crotty S; Harris AD
mSphere; 2022 Dec; 7(6):e0027922. PubMed ID: 36321826
[TBL] [Abstract][Full Text] [Related]
49. Multiplex Antibody Analysis of IgM, IgA and IgG to SARS-CoV-2 in Saliva and Serum From Infected Children and Their Close Contacts.
Dobaño C; Alonso S; Vidal M; Jiménez A; Rubio R; Santano R; Barrios D; Pons Tomas G; Melé Casas M; Hernández García M; Girona-Alarcón M; Puyol L; Baro B; Millat-Martínez P; Ajanovic S; Balanza N; Arias S; Rodrigo Melero N; Carolis C; García-Miquel A; Bonet-Carné E; Claverol J; Cubells M; Fortuny C; Fumadó V; Codina A; Bassat Q; Muñoz-Almagro C; Fernández de Sevilla M; Gratacós E; Izquierdo L; García-García JJ; Aguilar R; Jordan I; Moncunill G
Front Immunol; 2022; 13():751705. PubMed ID: 35154094
[TBL] [Abstract][Full Text] [Related]
50. A longitudinal seroepidemiology study to evaluate antibody response to SARS-CoV-2 virus infection and vaccination in children in Calgary, Canada from July 2020 to April 2022: Alberta COVID-19 Childhood Cohort (AB3C) Study.
Doucette EJ; Gray J; Fonseca K; Charlton C; Kanji JN; Tipples G; Kuhn S; Dunn J; Sayers P; Symonds N; Wu G; Freedman SB; Kellner JD
PLoS One; 2023; 18(4):e0284046. PubMed ID: 37023007
[TBL] [Abstract][Full Text] [Related]
51. Evaluation of the Roche SARS-CoV-2 Rapid Antibody Test in Samples from Vaccinated Individuals.
Hayer J; Urlaub E
Microbiol Spectr; 2022 Jun; 10(3):e0270921. PubMed ID: 35575594
[TBL] [Abstract][Full Text] [Related]
52. SARS-CoV-2 vaccination elicits unconventional IgM specific responses in naïve and previously COVID-19-infected individuals.
Ruggiero A; Piubelli C; Calciano L; Accordini S; Valenti MT; Carbonare LD; Siracusano G; Temperton N; Tiberti N; Longoni SS; Pizzato M; Accordini S; ; Fantoni T; Lopalco L; Beretta A; Bisoffi Z; Zipeto D
EBioMedicine; 2022 Mar; 77():103888. PubMed ID: 35196644
[TBL] [Abstract][Full Text] [Related]
53. Antibody responses after a single dose of ChAdOx1 nCoV-19 vaccine in healthcare workers previously infected with SARS-CoV-2.
Havervall S; Marking U; Greilert-Norin N; Ng H; Gordon M; Salomonsson AC; Hellström C; Pin E; Blom K; Mangsbo S; Phillipson M; Klingström J; Hober S; Nilsson P; Åberg M; Thålin C
EBioMedicine; 2021 Aug; 70():103523. PubMed ID: 34391088
[TBL] [Abstract][Full Text] [Related]
54. Superior neutralizing response after first versus second SARS-CoV-2 infection in fully vaccinated individuals.
Rivas G; Labiod N; Luczkowiak J; Lasala F; Rolo M; Mancheño-Losa M; Rial-Crestelo D; Lora-Tamayo J; Pérez-Rivilla A; Folgueira MD; Delgado R
J Med Virol; 2023 Nov; 95(11):e29225. PubMed ID: 37971751
[TBL] [Abstract][Full Text] [Related]
55. Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial.
Chen GL; Li XF; Dai XH; Li N; Cheng ML; Huang Z; Shen J; Ge YH; Shen ZW; Deng YQ; Yang SY; Zhao H; Zhang NN; Zhang YF; Wei L; Wu KQ; Zhu MF; Peng CG; Jiang Q; Cao SC; Li YH; Zhao DH; Wu XH; Ni L; Shen HH; Dong C; Ying B; Sheng GP; Qin CF; Gao HN; Li LJ
Lancet Microbe; 2022 Mar; 3(3):e193-e202. PubMed ID: 35098177
[TBL] [Abstract][Full Text] [Related]
56. mRNA-based SARS-CoV-2 Comirnaty vaccine elicits weak and short specific memory B cell response in individuals with no previous infection.
Casado JL; Vizcarra P; Martín-Hondarza A; Gómez-Maldonado S; Muedra-Sánchez M; Del Pino J; Mirabella IG; Martín-Colmenarejo S; Haemmerle J; Fernández-Escribano M; Vallejo A
Front Immunol; 2023; 14():1127379. PubMed ID: 37457694
[TBL] [Abstract][Full Text] [Related]
57. [Monitoring of anti-SARS-CoV-2 IgG antibody immune responses in two cohorts of Hungarian healthcare workers following infection or immunization].
Gervain J; Szabóné Bartha K; Bakiné Hodovánszky E; Kadlecsik L; Herczeg R; Gyenesei A; Simon J
Orv Hetil; 2022 Mar; 163(12):455-462. PubMed ID: 35306478
[TBL] [Abstract][Full Text] [Related]
58. Achievement of sufficient antibody response after a fourth dose of wild-type SARS-CoV-2 mRNA vaccine in nursing home residents.
Chong Y; Goto T; Watanabe H; Tani N; Yonekawa A; Ikematsu H; Shimono N; Tanaka Y; Akashi K
Immun Inflamm Dis; 2023 Aug; 11(8):e962. PubMed ID: 37647452
[TBL] [Abstract][Full Text] [Related]
59. Comparative kinetics of SARS-CoV-2 anti-spike protein RBD IgGs and neutralizing antibodies in convalescent and naïve recipients of the BNT162b2 mRNA vaccine versus COVID-19 patients.
Trougakos IP; Terpos E; Zirou C; Sklirou AD; Apostolakou F; Gumeni S; Charitaki I; Papanagnou ED; Bagratuni T; Liacos CI; Scorilas A; Korompoki E; Papassotiriou I; Kastritis E; Dimopoulos MA
BMC Med; 2021 Aug; 19(1):208. PubMed ID: 34420521
[TBL] [Abstract][Full Text] [Related]
60. Healthcare Workers in South Korea Maintain a SARS-CoV-2 Antibody Response Six Months After Receiving a Second Dose of the BNT162b2 mRNA Vaccine.
Choi JH; Kim YR; Heo ST; Oh H; Kim M; Lee HR; Yoo JR
Front Immunol; 2022; 13():827306. PubMed ID: 35173736
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
